Tozaro

Tozaro is a private, pre-revenue platform company addressing critical bottlenecks in viral vector manufacturing for cell and gene therapies. Its core technology involves the in silico design and chemical synthesis of custom 'smart polymer' affinity ligands, which aim to offer faster development, gentler purification, and improved analytics compared to conventional, biologically-derived ligands. With a recent £6 million funding round and a seasoned leadership team, the company is positioned to scale its technology and establish partnerships within the rapidly growing advanced therapy sector.

Integrated platform using molecular modeling, machine learning, and chemical synthesis to design and manufacture custom synthetic affinity ligands ('smart polymers') for viral vector purification and analytics.

Tozaro competes with large chromatography resin vendors (e.g., Cytiva, Thermo Fisher) who offer biological ligand-based products and have dominant market share. It also faces potential competition from other startups developing alternative synthetic affinity ligands (e.g., peptide-based) or novel purification modalities. Its differentiation lies in its fully chemical, rationally designed polymer platform.